PNEX.D logo

Pharnext OTCPK:PNEX.D Stock Report

Last Price

US$0.50

Market Cap

US$270.1k

7D

0%

1Y

n/a

Updated

18 Dec, 2022

Data

Company Financials +

PNEX.D Stock Overview

Pharnext SA, a clinical-stage biopharmaceutical company, engages in the development of therapies for neurodegenerative diseases with high unmet medical needs.

PNEX.D fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health2/6
Dividends0/6

Pharnext SA Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Pharnext
Historical stock prices
Current Share Price€0.50
52 Week High€550.00
52 Week Low€0.50
Beta1.76
1 Month Change0%
3 Month Changen/a
1 Year Changen/a
3 Year Change-100.00%
5 Year Changen/a
Change since IPO-100.00%

Recent News & Updates

Recent updates

Shareholder Returns

PNEX.DUS BiotechsUS Market
7D0%0.9%0.4%
1Yn/a10.3%28.8%

Return vs Industry: Insufficient data to determine how PNEX.D performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how PNEX.D performed against the US Market.

Price Volatility

Is PNEX.D's price volatile compared to industry and market?
PNEX.D volatility
PNEX.D Average Weekly Movementn/a
Biotechs Industry Average Movement11.6%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: PNEX.D's share price has been volatile over the past 3 months.

Volatility Over Time: Insufficient data to determine PNEX.D's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
2007n/aJoshua Schaferhttps://pharnext.com

Pharnext SA, a clinical-stage biopharmaceutical company, develops therapies for orphan and common neurodegenerative diseases in France. The company’s products include SYNGILITY that has completed Phase III trial for the treatment of Charcot-Marie-Tooth disease type 1A; and PXT864, which has completed Phase II clinical trial to treat Alzheimer’s disease, as well as Parkinson’s disease and amyotrophic lateral sclerosis. It also develops PLEOTHERAPY, a big genetic data and artificial intelligence platform.

Pharnext SA Fundamentals Summary

How do Pharnext's earnings and revenue compare to its market cap?
PNEX.D fundamental statistics
Market capUS$270.08k
Earnings (TTM)-US$38.34m
Revenue (TTM)US$2.89m

0.1x

P/S Ratio

0.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PNEX.D income statement (TTM)
Revenue€2.72m
Cost of Revenue€0
Gross Profit€2.72m
Other Expenses€38.90m
Earnings-€36.17m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-9.20
Gross Margin100.00%
Net Profit Margin-1,328.79%
Debt/Equity Ratio-85.6%

How did PNEX.D perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.